Ho Young Huh

Calibra Medical LLC develops and markets medical devices and technologies in the diabetes sector. Its products include finesse and insulin delivery devices. The company was founded by Daniel Hawkins and Clifton A. Alferness in 2004 and is headquartered in Wayne, PA.

Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA.

Konus Advisory Group, Inc. operated as a boutique advisory firm. It served the healthcare industries in markets including Asia, Latin America, and the Middle East. The firm provided targeted consulting to select clients as they navigate new geographies, advising both the United States and European organizations. The company was founded by Michael Masterson, Nevan Charles Elam and Hoyoung Huh in 2012 and was headquartered in Menlo Park, CA.

McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY.

EOS SpA engages in the manufacture of biopharmaceutical products. The company was founded by Silvano Spinelli, Gabriella Camboni, Ennio Cavalletti and Jacques Theurillat in June 2006 and is headquartered in Milan, Italy.

Interplast is a group of individuals founded by Dr. Laub from Stanford University who are concerned with the maldistribution of medicine. Interplast is based in Sunnyvale, CA. The non-profit company provides direct care to people who do not have access to surgery and educate professionals. The group has inspired thousands of international humanitarian trips around the world by many surgeons who are motivated to change lives through plastic and reconstructive surgery.

CytomX Therapeutics Holdings LLC engaged in the development of new generation targeted antibody therapeutics. The company was founded by Frederick W. Gluck on January 31, 2008 and is headquartered in Santa Barbara, CA.

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.

Synchronicity Pharma, Inc. discovers, develops and commercializes novel therapeutics. Its products identify components of the circadian system that can be targeted to treat metabolic and related disorders, such as diabetes, obesity, and cardiovascular diseases. The company was founded by Ross S. Bersot, Joseph S. Takahashi, Masashi Yanagisawas and Ron Evans in 2008 and is headquartered in San Jose, CA.

StemPar Sciences, Inc. develops cancer drugs treatments. It provides cancer drugs that attack solid tumors by simultaneously disrupting their source of energy and their ability to repair chemotherapy/radiation induced DNA damage. The company was founded by Hoyoung Huh and Mircea Florin Mihaescu in 2012 and is headquartered in Mill Valley, CA.

Resurge International operates surgical care facilities for poor children and adults.

Ascendancy Healthcare, Inc. engages in the commercialization of pharmaceutical productS. It enables product entry by providing clinical, regulatory and commercial expertise and oversight along with funding. The company was founded by Arthur Joseph Higgins and Sanford S. Zweifach on November 21, 2011 and is headquartered in San Francisco, CA.

Quintessa Investment acts as alternative investment manager. It is engaged in financial investment activities. The company was founded on January 13, 2011 and is headquartered in Seoul, South Korea.

pH Pharma Co. Ltd. engages in the developing and manufacturing of bio-pharmaceuticals. Its products include php-303, php-201, ab-101, nuvesse, alpine and torpedo products. The company was founded by Ho Young Huh on September 22, 2015 and is headquartered in Seoul, South Korea.

Eidos Therapeutics, Inc. focuses on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). Its product include the AG10, an orally-administered small molecule designed to potently stabilize TTR, suggesting a treatment with the potential to halt the progression of ATTR. The company was founded by Graef Isabella and Alhamadsheh Mamoun on August 6, 2013 and is headquartered in San Francisco, CA.

Part of Peak Bio, Inc., Peak Bio Co. Ltd. is a South Korean clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and inflammation. Peak Bio's location is in Seongnam, South Korea. The private company's lead product candidate, php-303, is a small molecule currently in phase II clinical study for the orphan disease alpha1 anti-trypsin deficiency. Peak Bio has successfully completed phase I trials, demonstrating dose-dependent pharmacokinetics and establishing a dose for upcoming clinical trials. The company's cancer platform includes novel payloads and antibody-drug-conjugates (ADC) to address unmet needs in cancer care. The company was founded in 2015, and the CEO is Ho Young Huh. Peak Bio Co. was acquired by Ignyte Acquisition Corp. on November 01, 2022 for $353.84 million.